FDA Approves Lebrikizumab for Patients with Atopic Dermatitis
FDA Approval for Lebrikizumab
The FDA approved lebrikizumab (Ebglyss; Eli Lilly) for treating patients aged 12 and older with moderate to severe atopic dermatitis (AD) who weigh at least 88 pounds.
This approval introduces a new first-line biologic treatment targeting patients inadequately controlled by topical therapies. Lebrikizumab works as an interleukin (IL)-13 inhibitor, effectively preventing skin spongiosis and alleviating itching.
Dosage and Administration
- The initial dose is 500 mg (two 250 mg injections), administered at weeks 0 and 2.
- Afterward, a maintenance dose of 250 mg is given every 2 weeks until week 16 or until a sufficient clinical response is achieved.
- Post-response, maintenance can transition to a monthly injection or 250 mg every 4 weeks.
Lilly has confirmed that lebrikizumab will soon be available in the US, with plans to collaborate with insurers and health systems to facilitate access.
Previously, lebrikizumab received approval from the European Commission in 2023 and is predicted to gain approval in additional markets.
Conclusion: A New Hope for Eczema Patients
Today’s approval supports those living with eczema, as Ebglyss provides a targeted approach to significantly reduce inflammation.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.